Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study.
about
Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog TherapyCurrent and future directions for treating hepatitis B virus infectionKinetics and prediction of HBsAg loss during long-term therapy with nucleos(t)ide analogues of different potency in patients with chronic hepatitis BOff-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis BLong-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection.Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir Therapy.Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analoguesHBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients.Current treatment of hepatitis B virus infections.Virological and Clinical Characteristics of Hepatitis B Virus Genotype A.Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia.When can we stop nucleoside analogues in patients with chronic hepatitis B?Analysis of HBsAg using high-sensitivity HBsAg assays in hepatitis B virus carriers in whom HBsAg seroclearance was confirmed by conventional assays.Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy.Clinical outcomes after spontaneous and nucleos(t)ide analogue-treated HBsAg seroclearance in chronic HBV infection.α-Fetoprotein level-dependent early hepatitis B surface antigen decline during entecavir therapy in chronic hepatitis B with hepatitis flare.Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability.Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naïve chronic hepatitis B patients.Risk of hepatocellular carcinoma in cirrhotic hepatitis B virus patients during nucleoside/nucleotide analog therapy.Loss of hepatitis B surface antigen in a real-life clinical cohort of patients with chronic hepatitis B virus infection.HLA-DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleot(s)ide analogue therapy.JSH Guidelines for the Management of Hepatitis B Virus Infection.Great and rapid HBsAg decline in patients with on-treatment hepatitis flare in early phase of potent antiviral therapy.Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up.Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B.Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?Viral Biomarkers in Chronic HBeAg Negative HBV Infection
P2860
Q26740161-1FE64475-FB34-4D77-8B98-68BA939DC042Q26851240-FDC5A308-DF52-4746-9325-F6087681EF3CQ33721394-F7DE6571-C7B3-450E-8FCE-093DC9E0F706Q35961444-3FCB5BCC-103A-4F19-8882-1FCDC2B482A8Q36401963-ABBDDAFC-D2DE-4D39-9DE1-750CF2BBE20CQ36797804-AA423126-0B51-44C3-BC2B-C7B65FCD3954Q38224440-F876433F-0A82-459C-9FF3-FA5A0822998FQ38295840-3817FC31-0057-46A8-854E-275E1BB7A35EQ38553056-0C343FC7-A088-4E41-AED4-FC97273B76C2Q38661138-A20B7430-80E5-456C-8765-D781D004EEE6Q38805019-7D718ECC-E062-440E-8D9E-230C664EE9E8Q39067306-80DFC6B8-2A3E-4B34-A4E9-0B49EC30DAC6Q40051443-0E09C80F-8527-4B25-AE74-802ABD45AE6BQ40073140-574D97A9-EFA5-4CBB-9507-76A15ED352AFQ40717249-9A43D5D2-F3E8-4C99-96C3-53265655E977Q40769626-C6D91CEE-E257-4D4F-85AB-8493AE11E48FQ41249783-953F4E7C-F80A-441A-BF03-8308ECBD3156Q41719578-E1E60280-5452-435B-96F7-15F10322B511Q41730134-745FBD09-12B9-4B7A-BC80-EC8B8E108040Q42198656-3FD529E6-1DE2-4309-9557-A1A693F269A4Q42201273-072422B8-FD24-48BC-A107-6E4E1CE25F40Q42244740-F36CB79A-6380-42EA-87E8-A29824235DC6Q47570782-9C139D07-6624-45AF-86E3-FF797568FEB6Q51217648-61B8B8F3-0BC8-4806-868C-72F24FC4DF94Q54088746-532FAAD9-0068-45B3-852F-ED0391BD865CQ54217690-03C65F13-A88A-4957-B8DA-D1FF1C064409Q59126856-3605A727-D54E-422E-A7DB-B0D23AA8B31D
P2860
Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Clearance of hepatitis B surface antigen during long-term nucleot
@nl
Clearance of hepatitis B surfa ...... nine-year longitudinal study.
@en
type
label
Clearance of hepatitis B surface antigen during long-term nucleot
@nl
Clearance of hepatitis B surfa ...... nine-year longitudinal study.
@en
prefLabel
Clearance of hepatitis B surface antigen during long-term nucleot
@nl
Clearance of hepatitis B surfa ...... nine-year longitudinal study.
@en
P2093
P2860
P1476
Clearance of hepatitis B surfa ...... nine-year longitudinal study.
@en
P2093
Fumitaka Suzuki
Hiromitsu Kumada
Hitomi Sezaki
Kenji Ikeda
Mariko Kobayashi
Masahiro Kobayashi
Norio Akuta
Satoshi Saitoh
Yasuji Arase
Yoshiyuki Suzuki
P2860
P304
P356
10.1007/S00535-012-0688-7
P577
2012-10-12T00:00:00Z